Literature DB >> 26453301

Cardiac Myosin-binding Protein C and Troponin-I Phosphorylation Independently Modulate Myofilament Length-dependent Activation.

Mohit Kumar1, Suresh Govindan1, Mengjie Zhang1, Ramzi J Khairallah1, Jody L Martin1, Sakthivel Sadayappan1, Pieter P de Tombe2.   

Abstract

β-Adrenergic stimulation in heart leads to increased contractility and lusitropy via activation of protein kinase A (PKA). In the cardiac sarcomere, both cardiac myosin binding protein C (cMyBP-C) and troponin-I (cTnI) are prominent myofilament targets of PKA. Treatment of permeabilized myocardium with PKA induces enhanced myofilament length-dependent activation (LDA), the cellular basis of the Frank-Starling cardiac regulatory mechanism. It is not known, however, which of these targets mediates the altered LDA and to what extent. Here, we employed two genetic mouse models in which the three PKA sites in cMyBP-C were replaced with either phospho-mimic (DDD) or phospho-null (AAA) residues. AAA- or DDD-permeabilized myocytes (n = 12-17) were exchanged (~93%) for recombinant cTnI in which the two PKA sites were mutated to either phospho-mimic (DD) or phospho-null (AA) residues. Force-[Ca(2+)] relationships were determined at two sarcomere lengths (SL = 1.9 μm and SL = 2.3 μm). Data were fit to a modified Hill equation for each individual cell preparation at each SL. LDA was indexed as ΔEC50, the difference in [Ca(2+)] required to achieve 50% force activation at the two SLs. We found that PKA-mediated phosphorylation of cMyBP-C and cTnI each independently contribute to enhance myofilament length-dependent activation properties of the cardiac sarcomere, with relative contributions of ~67 and ~33% for cMyBP-C for cTnI, respectively. We conclude that β-adrenergic stimulation enhances the Frank-Starling regulatory mechanism predominantly via cMyBP-C PKA-mediated phosphorylation. We speculate that this molecular mechanism enhances cross-bridge formation at long SL while accelerating cross-bridge detachment and relaxation at short SLs.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Frank-Starling Mechanism; contractile protein; heart; mouse; protein kinase A (PKA); signaling; β-adrenergic stimulation

Mesh:

Substances:

Year:  2015        PMID: 26453301      PMCID: PMC4705930          DOI: 10.1074/jbc.M115.686790

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

Review 1.  Structure, interactions and function of the N-terminus of cardiac myosin binding protein C (MyBP-C): who does what, with what, and to whom?

Authors:  Mark Pfuhl; Mathias Gautel
Journal:  J Muscle Res Cell Motil       Date:  2012-04-20       Impact factor: 2.698

2.  Sarcomere length dependence of power output is increased after PKA treatment in rat cardiac myocytes.

Authors:  Laurin M Hanft; Kerry S McDonald
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-27       Impact factor: 4.733

Review 3.  The Anrep effect: 100 years later.

Authors:  Horacio E Cingolani; Néstor G Pérez; Oscar H Cingolani; Irene L Ennis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-11-16       Impact factor: 4.733

Review 4.  Tuning the molecular giant titin through phosphorylation: role in health and disease.

Authors:  Carlos Hidalgo; Henk Granzier
Journal:  Trends Cardiovasc Med       Date:  2013-01-05       Impact factor: 6.677

Review 5.  Cardiac MyBP-C regulates the rate and force of contraction in mammalian myocardium.

Authors:  Richard L Moss; Daniel P Fitzsimons; J Carter Ralphe
Journal:  Circ Res       Date:  2015-01-02       Impact factor: 17.367

Review 6.  Integration of troponin I phosphorylation with cardiac regulatory networks.

Authors:  R John Solaro; Marcus Henze; Tomoyoshi Kobayashi
Journal:  Circ Res       Date:  2013-01-18       Impact factor: 17.367

7.  Protein kinase A does not alter economy of force maintenance in skinned rat cardiac trabeculae.

Authors:  P P de Tombe; G J Stienen
Journal:  Circ Res       Date:  1995-05       Impact factor: 17.367

8.  Length-dependent changes in contractile dynamics are blunted due to cardiac myosin binding protein-C ablation.

Authors:  Ranganath Mamidi; Kenneth S Gresham; Julian E Stelzer
Journal:  Front Physiol       Date:  2014-12-02       Impact factor: 4.566

9.  Modulation of thin filament activation of myosin ATP hydrolysis by N-terminal domains of cardiac myosin binding protein-C.

Authors:  Betty Belknap; Samantha P Harris; Howard D White
Journal:  Biochemistry       Date:  2014-10-20       Impact factor: 3.162

10.  Visualization of cardiac muscle thin filaments and measurement of their lengths by electron tomography.

Authors:  Thomas Burgoyne; Farina Muhamad; Pradeep K Luther
Journal:  Cardiovasc Res       Date:  2008-01-04       Impact factor: 10.787

View more
  27 in total

1.  Phosphorylation of cardiac myosin-binding protein-C contributes to calcium homeostasis.

Authors:  Mohit Kumar; Kobra Haghighi; Evangelia G Kranias; Sakthivel Sadayappan
Journal:  J Biol Chem       Date:  2020-06-18       Impact factor: 5.157

2.  Myosin filament activation in the heart is tuned to the mechanical task.

Authors:  Massimo Reconditi; Marco Caremani; Francesca Pinzauti; Joseph D Powers; Theyencheri Narayanan; Ger J M Stienen; Marco Linari; Vincenzo Lombardi; Gabriella Piazzesi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-06       Impact factor: 11.205

3.  The force and stiffness of myosin motors in the isometric twitch of a cardiac trabecula and the effect of the extracellular calcium concentration.

Authors:  Francesca Pinzauti; Irene Pertici; Massimo Reconditi; Theyencheri Narayanan; Ger J M Stienen; Gabriella Piazzesi; Vincenzo Lombardi; Marco Linari; Marco Caremani
Journal:  J Physiol       Date:  2018-05-27       Impact factor: 5.182

4.  Titin strain contributes to the Frank-Starling law of the heart by structural rearrangements of both thin- and thick-filament proteins.

Authors:  Younss Ait-Mou; Karen Hsu; Gerrie P Farman; Mohit Kumar; Marion L Greaser; Thomas C Irving; Pieter P de Tombe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

5.  Restrictive Cardiomyopathy Troponin I R145W Mutation Does Not Perturb Myofilament Length-dependent Activation in Human Cardiac Sarcomeres.

Authors:  Alexey V Dvornikov; Nikolai Smolin; Mengjie Zhang; Jody L Martin; Seth L Robia; Pieter P de Tombe
Journal:  J Biol Chem       Date:  2016-08-24       Impact factor: 5.157

6.  Shortening the thick filament by partial deletion of titin's C-zone alters cardiac function by reducing the operating sarcomere length range.

Authors:  Mei Methawasin; Gerrie P Farman; Shawtaroh Granzier-Nakajima; Joshua Strom; Balazs Kiss; John E Smith; Henk Granzier
Journal:  J Mol Cell Cardiol       Date:  2022-01-11       Impact factor: 5.000

7.  Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.

Authors:  Diederik W D Kuster; Thomas L Lynch; David Y Barefield; Mayandi Sivaguru; Gina Kuffel; Michael J Zilliox; Kyoung Hwan Lee; Roger Craig; Rajasekaran Namakkal-Soorappan; Sakthivel Sadayappan
Journal:  Cardiovasc Res       Date:  2019-12-01       Impact factor: 10.787

Review 8.  The continuing evolution of cardiac troponin I biomarker analysis: from protein to proteoform.

Authors:  Daniel Soetkamp; Koen Raedschelders; Mitra Mastali; Kimia Sobhani; C Noel Bairey Merz; Jennifer Van Eyk
Journal:  Expert Rev Proteomics       Date:  2017-10-16       Impact factor: 3.940

Review 9.  Skeletal myosin binding protein-C: An increasingly important regulator of striated muscle physiology.

Authors:  James W McNamara; Sakthivel Sadayappan
Journal:  Arch Biochem Biophys       Date:  2018-10-17       Impact factor: 4.013

10.  Fast-relaxing cardiomyocytes exert a dominant role in the relaxation behavior of heterogeneous myocardium.

Authors:  J Alexander Clark; Lorenzo R Sewanan; Jonas Schwan; Jonathan Kluger; Kenneth S Campbell; Stuart G Campbell
Journal:  Arch Biochem Biophys       Date:  2020-11-30       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.